First patients treated in robotic arrhythmia care programme at Overland Park Regional Medical Center

928
Dhanunjaya Lakkireddy performs the first robotic cardiac ablation procedure at OPRMC
Dhanunjaya Lakkireddy performs the first robotic cardiac ablation procedure at OPRMC

Stereotaxis announced today that HCA Midwest Health has launched a new robotic arrhythmia care programme based at Overland Park Regional Medical Center (OPRMC). Installation of the Stereotaxis Robotic Magnetic Navigation (RMN) System was recently completed, and the first patients have been successfully treated using the technology at OPRMC.

Stereotaxis’ partnership with HCA Midwest Health brings new treatment options for patients who have a cardiac arrhythmia, the company said in a press release. RMN uses robotics and magnetic fields to navigate a cardiac catheter directly from the tip. The technology consists of two robotically controlled magnets placed next to the operating table. During the procedure, a physician uses a computer interface to adjust the magnetic field around the patient and precisely direct and steer this cardiac ablation catheter in the heart.

Dhanunjaya Lakkireddy, Medical Director at Kansas City Heart Rhythm Institute, HCA Midwest Health and a partner of Midwest Heart and Vascular Specialists, authored a meta-analysis published in the Journal of Interventional Cardiac Electrophysiology, which emphasised the clinical value of robotics for the treatment of arrhythmias.

“The new cardiac arrhythmia labs at OPRMC were recently opened and are currently treating patients,” said Lakkireddy. “They represent the latest advances in the field of electrophysiology including robotic technology that enables improved outcomes and unparalleled safety for patients during cardiac ablation procedures. Robotics also allows OPRMC electrophysiologists to better address a range of complex arrhythmias that otherwise might not have been treated, providing hope to many patients who otherwise would have had no options for cardiac arrhythmia. We have observed the clinical value of robotic cardiac ablation and are excited to be providing patients convenient access to this technology.”

“As a world-renowned leader in electrophysiology research and patient care, Dr Lakkireddy recognises the significant patient, provider, and physician benefits of RMN. Stereotaxis technology affords OPRMC increased capabilities and a new and novel way to treat patients with cardiac arrhythmias,” said David Fischel, chairman and chief executive officer of Stereotaxis. “We look forward to supporting the Kansas City Heart Rhythm Institute and HCA Midwest Health as they improve patient care, advance clinical science, and grow a highly successful robotic arrhythmia care practice in Kansas City.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here